
Tenpoint Therapeutics is a global, commercial-ready biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting therapeutics for ophthalmic indications with significant unmet medical need, including presbyopia, cataracts, and geographic atrophy.
Our lead investigational asset, YUVEZZI™, is designed to be the first and only combination therapy for presbyopia and received FDA approval on January 28, 2026. We are actively advancing preparations for a commercial launch in the first half of 2026.
We know our people are the driving force behind the success of our mission and vision. That’s why we offer a competitive benefit package to attract the very best talent to our team and to take care of our employees and their families. Below is a snapshot of our U.S. benefits package for full-time employees.
For more information, visit www.tenpointherapeutics.com and follow us on LinkedIn, X, and Instagram
We are seeking a Thought Leader Liaison to join Tenpoint Therapeutics to be a trusted medical marketing strategic partner to influential optometrists and ophthalmologists in supporting education, insight generation, speaker development and peer to peer engagement. This is an external facing role responsible for identifying, developing, and sustaining strategic relationships with thought leaders, including Presbyopia and emerging refractive therapies. You will play a critical role in shaping the Presbyopia ecosystem during market development and early commercialization, informing strategy across medical, marketing, and commercial teams.
This position covers the Central region. Willingness to travel up to 60%-70%.
Thought Leader Engagement & Development
Speaker & Faculty Development
Scientific Exchange & Insights
Cross-Functional Collaboration
This role is primarily a field and desk-based job requiring the ability to operate a computer and communicate effectively in a remote work environment. The employee may be required to sit for extended periods, engage in video or phone meetings, and use standard office equipment. Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of the role.
EEO Statement
We are an Equal Opportunity Employer. Consistent with applicable law, all qualified applicants will receive consideration for employment without regard to race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity, Veteran status, or any other characteristic protected by applicable local laws, regulations and ordinances. If you need assistance and/or a reasonable accommodation due to a disability during the interview process, please place your accommodation request with your recruiting contact.

This page is intended for US audiences only.
Tenpoint Therapeutics Limited is a commercial-ready biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts, and geographic atrophy.
Its lead asset, BRIMOCHOL PF, is a novel, pupil-modulating investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that impacts nearly 128 million people in the U.S. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL PF, has filed the NDA and has received a Prescription Drug User Fee Act (PDUFA) date from the US FDA of January 28, 2026. Tenpoint Therapeutics’ leadership team includes ophthalmic industry luminaries with track records of successful approvals and commercialization of blockbuster treatments.